摘要
背景:二烯丙基二硫(DADS)在许多癌症中具有抗增殖活性。目的:探讨父亲和联合国的作用。其对乳腺癌干细胞(BCSCs)作用的机制。 方法:采用乳球形成法、葡萄糖消耗法、乳酸产生法和小鼠异种移植实验,探讨DADS在BCSCs中的作用。ATP酶活性测定采用免疫组织化学(IHC)和免疫组织化学(IHC)方法,探讨DADS在BCSCs中的作用机制。 结果:DADS能抑制BCSCs细胞的干细胞生长和糖代谢。小鼠异种移植实验表明,DADS能抑制BCSCs的增殖和转移。。然后,我们继续探讨dads在bcSCs中作用的机制,发现DADS通过靶向CD 44、丙酮酸激酶M2(Pkm 2)和AMP活化蛋白激酶(amp-activatedprotein kinase,ampk)sig而发挥作用。纳林路径。125例乳腺癌组织的IHC分析表明,CD 44、PKM 2和AMPK表达水平呈正相关。此外,CD 44、PKM 2和AMPK阳性表达SSION与患者整体生存(OS)和无病生存(DFS)相关. 结论:DADS通过抑制CD44/PKM2/AMPK抑制BCSCs细胞的增殖、转移和糖代谢。爸爸可能被用作潜在的杀手。用于乳腺癌治疗。
关键词: 二烯丙基二硫,乳腺癌干细胞,CD44,PKM2,AMPK,异种移植物。
图形摘要
Current Cancer Drug Targets
Title:Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling
Volume: 18 Issue: 6
关键词: 二烯丙基二硫,乳腺癌干细胞,CD44,PKM2,AMPK,异种移植物。
摘要: Background: It has been reported that diallyl disulfide (DADS) has anti-proliferative activity in many cancers.
Objective: The purpose of this study was to investigate the functions of DADS and the underlying mechanisms of its effect in breast cancer stem cells (BCSCs).
Method: Mammosphere formation assay, glucose consumption assay, lactate production assay and mouse xenograft experiments were performed to explore the functions of DADS in BCSCs. ATPase activity assay, western blotting and immunohistochemistry (IHC) assay were conduct to explore the mechanisms underlying the effects of DADS in BCSCs.
Results: The results showed that DADS suppressed cell stemness and glucose metabolism in BCSCs. In vivo mouse xenograft experiments showed that DADS inhibited the proliferation and metastasis of BCSCs. Then, we continued to explore the mechanisms underlying the effects of DADS in BCSCs and found that DADS acts by targeting CD44, Pyruvate kinase M2 (PKM2) and AMP-activated protein kinase (AMPK) signaling pathways. IHC analysis of 125 breast cancer patients’ tissues demonstrated that CD44, PKM2 and AMPK expression levels were positively correlated. In addition, positive CD44, PKM2 and AMPK expression was associated with poor patient overall survival (OS) and disease-free survival (DFS).
Conclusion: In summary, DADS suppresses cell stemness, proliferation, metastasis and glucose metabolism in BCSCs partly through the inhibition of CD44/PKM2/AMPK. DADS may be used as a potential therapy for breast cancer treatment.
Export Options
About this article
Cite this article as:
Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling, Current Cancer Drug Targets 2018; 18 (6) . https://dx.doi.org/10.2174/1568009617666171024165657
DOI https://dx.doi.org/10.2174/1568009617666171024165657 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Advances in the Treatment of Neurodegenerative Diseases and Epilepsy
Current Pharmaceutical Design Drug Delivery Systems for Chemotherapeutics through Selected Polysaccharidic Vehicles
Current Organic Chemistry Molecular Imaging with Nucleic Acid Aptamers
Current Medicinal Chemistry Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis
Current Molecular Medicine Recent Patents on Liposomal-Based Chemotherapeutics with a Triggered Release Mechanism
Recent Patents on Nanomedicine Nanoparticle-based Drug Delivery Systems for Solid Brain Tumors
Current Nanoscience Basal-like Breast Cancer: Comparison of Imaging Characteristics
Current Medical Imaging The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design Phosphoserine Aminotransferase has Conserved Active Site from Microbes to Higher Eukaryotes with Minor Deviations
Protein & Peptide Letters Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Biomarkers of Osteoarthritis: A Review of Recent Research Progress on Soluble Biochemical Markers, Published Patents and Areas for Future Development
Recent Patents on Biomarkers Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Current Pharmaceutical Design Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Pharmacological and Molecular Targets in Cellular Redox Status Maintenance)
Current Pharmaceutical Design Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets